Search clinical trials for: Risperidone Long-acting Injectable (LAI) 25 mg

Total 607 results

Janssen-Cilag S.p.A.

Completed

Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder
Northwestern University
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone

Schizophrenia | Schizoaffective Disorder

United States
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia

Schizophrenia | Schizoaffective Disorder

Korea, Republic of
Intra-Cellular Therapies, Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia

Schizophrenia

United States
Janssen Scientific Affairs, LLC

Completed

Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations

Schizophrenia | Bipolar Disorder

United States
Janssen Pharmaceutica N.V., Belgium

Completed

A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder

Bipolar Disorder

China, Taiwan, Colombia, India, Malaysia, Russian Federation, South Africa, Greece, Peru, Germany, Mexico, Lebanon, Indonesia, Philippines, Jordan
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age

HIV-1-infection

United States, Brazil, South Africa, Uganda, Botswana, Thailand
Janssen Pharmaceutica N.V., Belgium

Completed

A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis

Schizophrenia
Janssen Pharmaceutical K.K.

Completed

A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients

Schizophrenia
Janssen Pharmaceutica N.V., Belgium

Completed

Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of Psychosis

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.

Schizophrenia
Johnson & Johnson Pharmaceutical Research & Development...
Janssen, LP

Completed

A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder
Janssen Pharmaceutica N.V., Belgium

Completed

A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia

Psychotic Disorders | Schizophrenia
Janssen Korea, Ltd., Korea

Completed

An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder

Schizophrenia

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients.

Schizophrenia
Janssen Pharmaceutica N.V., Belgium

Completed

RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder
Janssen Cilag N.V./S.A.

Completed

A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode

Schizophrenia

South Africa
University of California, Los Angeles
National Institute of Mental Health (NIMH); Janssen Scientific Affairs, LLC

Completed

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

Schizophrenia

United States
Northwell Health
National Alliance for Research on Schizophrenia and Depression; The Zucker...

Terminated

Optimizing Response in Psychosis Study (ORP)

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Psychotic Disorder Not Otherwise Specified

United States
Seattle Institute for Biomedical and Clinical Research
Janssen, LP

Completed

A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence

Methamphetamine Dependence

United States
Janssen-Ortho Inc., Canada

Completed

A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis

Psychotic Disorders | Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder

Canada
Janssen-Ortho Inc., Canada

Terminated

A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication

Schizophrenia

Canada, United Kingdom, Australia, Ireland
Janssen-Cilag International NV

Completed

A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Psychotic Disorders | Schizophrenia

France, Poland, Germany, Spain, Slovenia, Bulgaria, Romania, Israel, Greece, Sweden, Turkey, Czech Republic, Hungary, Lithuania, Latvia, Portugal, Croatia, Slovakia, Austria, United Kingdom, Estonia, Ireland, Denmark, Saudi Arabia
Vanderbilt University
Ortho-McNeil Janssen Scientific Affairs, LLC

Completed

Does Risperidone Consta Reduce Relapse and Rehospitalization in Bipolar Disorder? (Consta)

Bipolar Disorder

United States
Janssen-Cilag International NV

Completed

InORS - International Observational Registry on Schizophrenia With Injectable Risperidone and Oral Antipsychotics

Schizophrenia

France, Germany, Spain, South Africa, Turkey, Greece, Czech Republic, Russian Federation
National Institute of Allergy and Infectious Diseases...
ViiV Healthcare

Active, not recruiting

More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (MOCHA)

HIV Infections

Thailand, United States, Botswana, Uganda, South Africa
Centre for Addiction and Mental Health

Recruiting

Does Psilocybin Require Psychedelic Effects to Treat Depression? (PSI-RIS)

Treatment-resistant Depression

Canada
Rovi Pharmaceuticals Laboratories

Completed

Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths (PRISMA-1)

Schizophrenia | Schizoaffective Disorder

Spain, South Africa, Russian Federation, Croatia
Instituto Nacional de Cardiologia Ignacio Chavez

Not yet recruiting

Empagliflozin for No-reflow Phenomenon in PCI for STEMI (EMPA-PCI)

STEMI | No-Reflow Phenomenon
Georgia Institute of Technology
University of Georgia; University of Illinois at Urbana-Champaign; National Institute... and other collaborators

Completed

TechSAge Tele Tai Chi for People Aging With Mobility Disabilities

Aging | Disability Physical

United States
Hospices Civils de Lyon

Completed

Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment (SOMILEO)

Enterostomy

France
Rovi Pharmaceuticals Laboratories

Completed

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia (PRISMA-3)

Acute Schizophrenia

United States, Ukraine
Dartmouth-Hitchcock Medical Center
Janssen, LP

Completed

Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder

Psychotic Disorders | Schizophrenia | Substance Abuse | Alcohol Abuse

United States
Novartis Pharmaceuticals

Completed

Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea (LARCID)

Chemotherapy-induced Diarrhea

Brazil
Creighton University

Withdrawn

Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function

Hypertension

United States
Boehringer Ingelheim

Completed

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

Schizophrenia | Alzheimer Disease

United States
Rovi Pharmaceuticals Laboratories

Completed

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension (PRISMA-3_OLE)

Schizophrenia

United States, Ukraine
Indivior Inc.

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

Schizophrenia

United States
Indivior Inc.

Completed

Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia

Schizophrenia

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

Psychotic Disorders | Schizophrenia

United States
Hospital Authority, Hong Kong
Janssen Pharmaceutica N.V., Belgium

Unknown

Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone

Psychotic Disorders | Schizophrenia | Schizophrenia, Paranoid | Schizophrenia, Catatonic | Schizophrenia, Disorganized

China
University of Sao Paulo General Hospital

Recruiting

iSGLT2 in Prevention of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing CABG Extracorporeal On-Pump (POST-CABGDM)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury | Coronary Artery Bypass Surgery

Brazil
National Taiwan University Hospital
Shin Kong Wu Ho-Su Memorial Hospital

Not yet recruiting

EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease (EMPA-PRED)

Heart Failure With Preserved Ejection Fraction | End Stage Renal Disease on Dialysis
St. Olavs Hospital
Aleris Helse

Completed

Serum Concentration of Tranexamic Acid After Topical Administration in Massive Weight Loss Skin Reducing Surgery

Bleeding | Surgical Wound

Norway
Pfizer

Completed

A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma

Healthy Participants

United States
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Recruiting

Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine (HOLA)

HIV-1 Infection

Spain
Centre for Addiction and Mental Health
Janssen Inc.

Recruiting

Risk of Breakthrough Symptoms With Long-Acting Injectable Medications

Schizophrenia | Schizophrenia Relapse

Canada
R-Pharm

Completed

A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer

Cancer

United States
Grünenthal GmbH
Grünenthal Colombiana S.A.

Completed

Pharmacokinetic Non-interaction Study With a Fixed-dose Combination Tablet With Tramadol and Diclofenac

Pharmacokinetics

Mexico
Boehringer Ingelheim

Completed

Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

Healthy

Germany

3

Subscribe